Level A· Stronger Clinical EvidenceMeta-analysisEurope PMCOpen access

The Role of NLRP3 Inflammasome in Obesity and PCOS-A Systematic Review and Meta-Analysis

Alenezi SA., Khan R., Snell L., Aboeldalyl S., Amer S.

Meta-analysis with a reported sample of 270 on Systemic / IV, published in Int J Mol Sci (2023) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Meta-analysis
Journal
Int J Mol Sci (2023)
Reported sample size
270
Source database
Europe PMC
PMID
37446154
PMCID
PMC10341879
DOI
10.3390/ijms241310976
Citations
31

Abstract (original English)

Inflammasomes have recently been implicated in the pathogenesis of several chronic inflammatory disorders, such as diabetes and obesity. The aim of this meta-analysis was to investigate the possible role of the NLRP3 inflammasome in obesity and polycystic ovarian syndrome (PCOS). A comprehensive search of electronic databases was conducted to identify studies investigating NLRP3 its related components (Caspase 1, ASC and IL-1β) in adipose tissue and/or blood from obese individuals compared to non-obese controls. Another search was conducted for studies investigating NLRP3 in PCOS women and animal models. The ssearched databases included Medline, EMBASE, Cochrane Library, PubMed, Clinicaltrials.gov, the EU Clinical Trials Register and the WHO International Clinical Trials Register. The quality and risk of bias for the included articles were assessed using the modified Newcastle-Ottawa scale. Data were extracted and pooled using RevMan software for the calculation of the standardized mean difference (SMD) and 95% confidence interval (CI). Twelve eligible studies were included in the obesity systematic review and nine in the PCOS review. Of the obesity studies, nine ( n = 270) were included in the meta-analysis, which showed a significantly higher adipose tissue NLRP3 gene expression in obese ( n = 186) versus non-obese ( n = 84) participants (SMD 1.07; 95% CI, 0.27, 1.87). Pooled

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
Adipose TissueAnimalsHumansMiceRatsPolycystic Ovary SyndromeObesityFemaleInflammasomesNLR Family, Pyrin Domain-Containing 3 Protein

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research